Indication
EBV-Positive DLBCL
3 clinical trials
5 products
Clinical trial
A Phase 1, Open-Label, Multicenter, Dose Escalation Study of SGR-1505 as Monotherapy in Subjects With Mature B-Cell MalignanciesStatus: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory LymphomasStatus: Recruiting, Estimated PCD: 2025-07-01
Product
SGR-1505Clinical trial
A Phase 2 Study of Acalabrutinib in Combination With Lisocabtagene Maraleucel in Relapsed/Refractory Aggressive B-cell LymphomasStatus: Recruiting, Estimated PCD: 2025-03-01
Product
ACALABRUTINIBProduct
Lisocabtagene maraleucelProduct
Lymphodepleting chemotherapy